Honokiol Improves Liver Steatosis in Ovariectomized Mice

Area of Science:

• Hepatology
• Endocrinology
• Pharmacology

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a prevalent liver condition linked to metabolic syndrome.
• Postmenopausal women with estrogen deficiency face an elevated risk of NAFLD progression.
• Estrogen offers protection against NAFLD, yet effective treatments for this demographic are lacking.

Purpose of the Study:

• To investigate the potential hepatoprotective effects of Honokiol (Ho) on NAFLD in a mouse model of estrogen deficiency.
• To evaluate Ho's impact on liver steatosis, inflammation, and lipid metabolism in ovariectomized (OVX) mice.

Main Methods:

• Ovariectomized (OVX) mice were divided into four groups: SHAM, OVX, OVX+β-estradiol, and OVX+Ho.
• Mice were administered diets with or without Ho (50 mg/kg) for 12 weeks.
• Measurements included body weight, fat, liver weight, hepatic steatosis, inflammatory markers, and plasma lipid levels.

Main Results:

• Honokiol administration reduced body weight, epidermal fat, and liver tissue weight compared to the OVX group.
• Ho significantly improved hepatic steatosis and decreased pro-inflammatory cytokine levels.
• Ho markedly downregulated plasma lipid levels, indicating improved lipid metabolism.

Conclusions:

• Honokiol effectively ameliorated OVX-induced fatty liver and inflammation in mice.
• Ho demonstrated beneficial effects on lipid metabolism associated with NAFLD.
• These findings suggest Honokiol holds potential as a hepatoprotective agent for NAFLD in postmenopausal women.